29 results
Thumbnail

D2.170 - The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season

Thumbnail

D2.171 - The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment

Thumbnail

D2.172 - Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions

Thumbnail

D2.173 - Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis

Thumbnail

D2.175 - TAPAS – non-inferiority of clinical effectiveness in children compared to adults: interim results of a long-term NIS

Thumbnail

D2.176 - Improved quality of life after PQ Grass in comparison to SLIT products in grass allergic patients

Thumbnail

D2.177 - The Efficacy of Sublingual Immunotherapy in Mild versus Moderate Atopic Dermatitis Among Children with House Dust Mite Allergic Rhinitis

Thumbnail

D2.178 - Allergen-specific IgE/IgG4 ratio as biomarker of allergen immunotherapy efficacy in house dust mite-sensitized allergic rhinitis

Thumbnail

D2.180 - Immunological evaluation of cat allergic individuals living with or without a cat